Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 11, Issue 512, Pages eaax0720
Publisher
American Association for the Advancement of Science (AAAS)
Online
2019-10-03
DOI
10.1126/scitranslmed.aax0720
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target
- (2019) Juliane Medler et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens
- (2018) Jeremy D. Waight et al. CANCER CELL
- Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
- (2018) Roberta Zappasodi et al. CANCER CELL
- Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies
- (2018) Xiaojie Yu et al. CANCER CELL
- The promise and challenges of immune agonist antibody development in cancer
- (2018) Patrick A. Mayes et al. NATURE REVIEWS DRUG DISCOVERY
- Structural principles of tumor necrosis factor superfamily signaling
- (2018) Éva S. Vanamee et al. Science Signaling
- Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
- (2018) Yingjie Nie et al. Science Signaling
- Structural principles of tumor necrosis factor superfamily signaling
- (2018) Éva S. Vanamee et al. Science Signaling
- Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer
- (2018) Yingjie Nie et al. Science Signaling
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome
- (2018) H Torrey et al. LEUKEMIA
- Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity
- (2018) Kamar-Sulu N. Atretkhany et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
- (2018) S. Michael Chin et al. Nature Communications
- Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice
- (2017) Megan Lo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
- (2017) Alice O. Kamphorst et al. SCIENCE
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- TNFR2: A Novel Target for Cancer Immunotherapy
- (2017) Éva S. Vanamee et al. TRENDS IN MOLECULAR MEDICINE
- Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs
- (2017) Heather Torrey et al. Science Signaling
- Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer
- (2017) Xin Chen et al. Science Signaling
- TNFR2: The new Treg switch?
- (2017) José L. Cohen et al. OncoImmunology
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion
- (2016) Martin Chopra et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
- (2016) Jeffrey S. Weber et al. ONCOLOGIST
- Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway
- (2016) Tao Zhao et al. Oncology Letters
- Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy
- (2016) Geoffrey S. Williams et al. Oncotarget
- PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
- (2016) Claud Grigg et al. Journal for ImmunoTherapy of Cancer
- Shedding of TNF receptor 2 by effector CD8+ T cells by ADAM17 is important for regulating TNF-α availability during influenza infection
- (2015) Matthew P. DeBerge et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a
- (2015) E. Arduin et al. MOLECULAR IMMUNOLOGY
- Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
- (2015) Abhisek Swaika et al. MOLECULAR IMMUNOLOGY
- FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
- (2015) Falk Nimmerjahn et al. TRENDS IN IMMUNOLOGY
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells
- (2014) X. Chen et al. JOURNAL OF IMMUNOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- TNF and MAP kinase signalling pathways
- (2014) Guadalupe Sabio et al. SEMINARS IN IMMUNOLOGY
- Rapid optimization and prototyping for therapeutic antibody-like molecules
- (2013) Lihui Xu et al. mAbs
- Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
- (2013) F. Mimoto et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Properties of mouse and human IgG receptors and their contribution to disease models
- (2012) P. Bruhns BLOOD
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3- Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells
- (2010) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Solution of the Structure of the TNF-TNFR2 Complex
- (2010) Y. Mukai et al. Science Signaling
- Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
- (2008) Seung Y. Chu et al. MOLECULAR IMMUNOLOGY
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now